EPZM News and Press, Epizyme Inc. From 01/27/22

One of the steepest decliners in the biotech sector Thursday was Epizyme (NASDAQ: EPZM) . The cancer-focused biotech saw its shares plummet 44% in value that day, on news of a dilutive secondary stock issue. Epizyme announced that it is floating nearly 56.7 million shares of its...

-- Preliminary TAZVERIK ® (tazemetostat) Net Product Revenue Expected to be Between $11.2-11.7 Million and Between $30.6-31.1 Million for 4Q 2021 and Full-Year 2021, Respectively; Preliminary TAZVERIK Commercial Net Sales Expected to be Between $7.0-7.5 Million and Between $2...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory stu...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today shared preclinical data and the Phase 1/1b trial design for EZM0414, the Company’s novel, first-...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced that new data from across its oncology portfolio will be presented at the upcoming 63rd Ameri...

Epizyme has been on my watch list for over a year now due to the company’s flagship product, TAZVERIK. Unfortunately, the company launched TAZVERIK right into strong COVID-19 headwinds. The company's earnings have been lackluster and the share price continues to hit new 52-week...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and intern...

Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcar...

Image source: The Motley Fool. Epizyme, inc (NASDAQ: EPZM) Q3 2021 Earnings Call Nov 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Epizyme, inc (EPZM) Q3 2021 Earnings Call Transcript

Start Time: 08:30 End Time: 09:03 Epizyme, Inc. (EPZM) Q3 2021 Earnings Conference Call November 09, 2021, 08:30 AM ET Company Participants Grant Bogle - President and CEO Shefali Agarwal - EVP, Chief Medical and Development Officer Craig West - VP, IR Conference Call Participants Peter Lawso...